Abstract: Methods and devices for the stabilization of heart tissue to treat congestive heart failure using a therapeutic composition are discussed. The therapeutic composition can comprise an elastin stabilization agent, a collagen stabilization agent, or a combination thereof and be applied to the pericardium, to the outer surface of the myocardium, or a combination thereof using a catheter type of device with an attached reservoir. Controlled placement and release of the therapeutic composition can be achieved using a delivery vehicle to formulate the composition.
Abstract: The present invention provides novel compositions and methods for repair and regeneration of tissues or organs of the body, especially mucosa in the gastrointestinal tract. The composition can be used as a pharmaceutical or nutraceutical to treat or prevent gastrointestinal cancer such as colorectal carcinoma, stomach cancer and esophagus cancer. The composition is in an oral dosage form and comprises edible oil homogenized with a sterol compound at a concentration of at least 0.5% by weight and edible wax at a concentration ranging from 3% to 30% by weight.
Abstract: The invention provides an organic material-immobilizing structure employing new immobilization means, characterized in that at least a part of the surface of the substrate is comprised of one or more members containing silicon oxide, the organic material is bound to the surface of the substrate through a binding domain bound to the organic material and containing an amino acid sequence capable of binding to silicon oxide, selected from the group consisting of amino acid sequences of SEQ ID NOS: 1 and 2: Val-Ser-Pro-Met-Arg-Ser-Ala-Thr-Thr-His-Thr-Val; and Ile-Pro-Met-His-Val-His-His-Lys-His-Pro-His-Val, and derivatives thereof.
Abstract: A tissue graft composition comprising liver basement membrane and a method of preparation of this tissue graft composition are described. The graft composition can be implanted to replace or induce the repair of damaged or diseased tissues.
Type:
Grant
Filed:
January 9, 2003
Date of Patent:
April 5, 2011
Assignee:
Purdue Research Foundation
Inventors:
Stephen Francis Badylak, Eric James Rodenberg
Abstract: Skin care formulations having tamanu oil in amounts providing effective rates of protection for antimicrobial and anti-aging properties, including but not limited to promoting the formation of new tissue, scar healing and skin repair, anti-inflammatory, anti-bacterial, anti-fungal, anti-oxidant, and combinations thereof.
Abstract: A pharmaceutical composition for preventing and/or treating bone loss is disclosed. The pharmaceutical composition includes an effective amount of a licorice, black bean, Cnidi Fructus, and buckhorn.
Abstract: A biomaterial prepared from a process comprising dehydrating the fish scales until the fish scales containing less than about 50% of water, and grinding the dehydrated fish scales into ground particles each having an average size of less than about 10,000 ?m in diameter, wherein the ground particles contain a mixture of sponge like matrix and powder is provided. The invention also provides a biomaterial prepared from fish scales by a process comprising subjecting the fish scales to a heat treatment at a temperature of less than about 200° C.
Type:
Application
Filed:
September 13, 2010
Publication date:
March 17, 2011
Applicant:
Body Organ Biomedical Corp.
Inventors:
Chien-Cheng LIN, Horng-Ji LAI, Shang-Ming LIN
Abstract: A method for treating oleoresin induced allergic dermatitis by topically contacting an affected area with a therapeutically effective amount of one or more biopolymers for a sufficient amount of time to enable the one or more biopolymers to have an effect and removing the one or more biopolymers from the affected area. The oleoresin can be urushiol, isosolenopsin A, or a combination thereof. The one or more biopolymer can be albumin. The one or more biopolymers can provide a localized anti-inflammatory effect.
Abstract: Shark cartilage extract has been shown to be an antagonist of parathyroid hypertensive factor (PHF). In view of this, shark cartilage extract can be used to treat conditions related to excessive PHF activity. Such diseases include hypertension and some other diseases related to intracellular calcium elevation. Methods for producing the shark cartilage extract and methods for administering the extract are disclosed.
Type:
Grant
Filed:
May 29, 2007
Date of Patent:
March 15, 2011
Assignee:
FX Life Sciences AG
Inventors:
Peter K. T. Pang, Jacqueline J. Shan, Kam Chiu
Abstract: A composition of matter for an analgesia and its method of use is disclosed. The method of use is for the treatment of chronic pain, especially to the treatment of heretofore intractable pain as associated with advanced cancer. The pain associated with neurological conditions, rheumatoid arthritis, viral infections and lesions is also contemplated. The method includes administering to a host an alpha-neurotoxin that is characterized by its ability to blocking of the action of acetylcholine at nicotinic acetylcholine receptors.
Abstract: The invention provides isolated N-methyl-D-aspartate type 3B (NR3B) polypeptides, functional fragments and peptides, encoding nucleic acid molecules and polynucleotides, and specific antibodies. Also provided are excitatory glycine receptors, containing either NR3B or NR3A polypeptides. Further provided are methods for detecting excitatory glycine receptor ligands, agonists and antagonists. The invention also provides related diagnostic and therapeutic methods.
Type:
Application
Filed:
July 23, 2010
Publication date:
February 24, 2011
Applicants:
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., YALE UNIVERSITY
Inventors:
STUART A. LIPTON, DONGXIAN ZHANG, JON E. CHATTERTON, KEVIN A. SEVARINO, MARC AWOBULUYI
Abstract: The invention relates to soft gelatin capsules containing at least one pharmaceutical, wherein the capsule shell includes carrageenan and cold water fish gelatin or a mixture of cold fish gelatin and warm fish gelatin.
Type:
Application
Filed:
January 29, 2009
Publication date:
February 24, 2011
Applicant:
AYANDA AS
Inventors:
Ingvild Johanne Haug, Kurt Ingar Draget
Abstract: The present invention provides chemokine receptor antibodies that selectively bind to an activated form of the receptor but not to a non activated form of the receptor. In particular, the current invention provides phosphospecific chemokine receptor antibodies. The antibodies can be used in several diagnostic, screening and purification methods.
Type:
Grant
Filed:
June 30, 2006
Date of Patent:
February 22, 2011
Assignees:
Washington University in St. Louis, Dana-Farber Cancer Institute, Inc.
Abstract: A method for detecting or monitoring the presence of protein fragments, cleaved at novel cleaving sites near the N-terminal part of the collagen IX alpha 1 chain, close to the C-terminal part of the NC4 domain, and at the COL3 domain close to the NC3 domain. Neoepitope antibodies against the neoepitopes were created by the cleavages and an epitope in the cleaved N-terminal part of the NC4 domain unique to collagen IX. A diagnostic kit and antibodies useful in carrying out such methods are also presented.
Type:
Grant
Filed:
February 26, 2008
Date of Patent:
February 22, 2011
Assignee:
Anamar Medical AB
Inventors:
Mikael Danfelter, Patrik Önnerfjord, Dick HeinegÅrd
Abstract: Human P4HA genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of P4HA are provided.
Type:
Grant
Filed:
June 20, 2005
Date of Patent:
February 15, 2011
Assignee:
Exelixis, Inc.
Inventors:
Lori S. Friedman, Helen Francis-Lang, Annette L. Parks, Kenneth James Shaw, Timothy S. Heuer, Lynn Margaret Bjerke
Abstract: Human PDE genes are identified as modulators of the IGFR pathway and thus are therapeutic targets for disorders associated with defective IGFR function Methods for identifying modulators of IGFR comprising screening for agents that modulate the activity of PDE are provided.
Type:
Grant
Filed:
March 10, 2005
Date of Patent:
February 15, 2011
Assignee:
Exelixis, Inc.
Inventors:
Lori Friedman, Helen Francis-Lang, Annette L. Parks, Kenneth James Shaw, Lynn Margaret Bjerke, Timothy S. Heuer
Abstract: The present invention relates to an assay which can be used on nasal secretions. The assay is used to determine the cause of nasal secretions, for example whether the secretions are due to an allergic reaction or a non-allergic reaction.
Abstract: A method of identifying altered biomarker expression levels in a human serum specimen to diagnose asthma or non-small celled lung cancers in humans. The existence of asthma or non-small celled lung cancers in a patient can be determined by subjecting a blood sample from the patient to a simple blood test to determine the expression levels of certain specific biomarkers. The expression levels of the specific biomarkers are compared to ranges of expression levels for the same biomarkers which are indicative of individuals known to have asthma, non-small cell lung cancers, or neither. Comparing the expression levels will determine the existence or non-existence of asthma or non-small cell lung cancer.
Type:
Grant
Filed:
September 11, 2008
Date of Patent:
February 15, 2011
Assignee:
Cancer Prevention and Cure, Ltd.
Inventors:
Robert T. Streeper, Elzbieta Izbicka, Sung H. Baek
Abstract: A natural pharmaceutical preparation for treating hypoproteinemia, includes at least one member selected from the group consisting of a drug of increasing human serum albium, a drug of improving and enhance immunity, a drug of treating hepatitis B, a drug of treating Hepatitis C, a drug of treating acquired immune deficiency syndrome (AIDS), a drug of treating Tuberculosis, a drug of treat Fibrosis, a drug of treating hydrothorax, a drug of easing pain, a drug of stopping diarrhea, a drug of arresting coughing, a drug of reducing inflammation, and a drug of increasing urine.
Abstract: The invention relates to a method of collecting saliva from the oral cavity for detecting a test substance, comprising the steps of (a) cleaning the oral cavity, (b) stimulating saliva secretion with a saliva-collecting solution, (c) removing the saliva-saliva collecting solution mixture from the oral cavity and collecting it in a container (1), (d) transferring the saliva-saliva collecting solution mixture into a sealable collection vessel.
Abstract: Disclosed is a sugar and/or a sugar alcohol as a substance for suppressing dephosphorylation reaction of a phosphorylated coenzyme. Also disclosed is a method for stabilizing a phosphorylated coenzyme which is characterized by having at least a substance for suppressing dephosphorylation reaction of the phosphorylated coenzyme coexist with the phosphorylated coenzyme.
Abstract: An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs one or more salts from a group of salts comprising sodium citrate, sodium acetate, sodium gluconate, ammonium sulfate, sodium chloride, sodium sulfate and ammonium chloride in two initial fractionation steps, followed by diafiltration to remove those salts employed. A process which employs alcohol via the process of the disclosed inventive method is also disclosed.
Type:
Grant
Filed:
February 21, 2006
Date of Patent:
February 1, 2011
Assignee:
Plasma Technologies, LLC
Inventors:
Gene Zurlo, Dennis Curtin, Allan L. Louderback
Abstract: An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs sodium citrate in two initial fractionation steps, followed by diafiltration to remove sodium citrate.
Type:
Grant
Filed:
September 22, 2005
Date of Patent:
February 1, 2011
Assignee:
Plasma Technologies, LLC
Inventors:
Eugene J. Zurlo, Dennis D. Curtin, Allan L. Louderback
Abstract: The invention relates to a system and method for isolating particles from a biological fluid, including: obtaining a sample of biological fluid from a source (e.g. a patient) in which the sample contains particles of multiple sample particle types; tagging particles in the sample with tagging agents, including mixing the sample with a solution of magnetic tagging agents that selectively bind to particles of at least one of the sample particle types, thereby forming a group of tagged particles in the sample; passing the sample through a magnetic conduit having a magnetic field that interacts with at least some of the tagged particles; sorting the particles of the sample into multiple groups based on the interaction between the tagged particles and the magnetic field; and optionally returning selected portions of the processed fluid back to its source with or without the addition of appropriate therapeutic agents.
Abstract: Compounds of Formula I that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.
Type:
Application
Filed:
June 4, 2010
Publication date:
January 27, 2011
Inventors:
Vincent Mascitti, Kim F. McClure, Michael J. Munchhof, Ralph P. Robinson
Abstract: Cells, compositions, and methods of cell therapy for administering a therapeutically effective amount of stem cells or cell concentrate to achieve accelerated wound healing of normal and chronic wounds, while minimizing the formation of scar tissue.
Type:
Application
Filed:
November 15, 2008
Publication date:
January 27, 2011
Inventors:
Debrabrata Banerjee, Prasun J. Mishra, Pravin J. Mishra, Joseph R. Bertino, Rita Humeniuk, John Glod
Abstract: A therapeutic agent for fibromyalgia syndrome or therapeutic agent for pain caused by vascular smooth muscle spasm including a) one or more compounds selected from a group consisting of RNA, ribonucleotide and ribonucleoside, b) one or more compounds selected from a group consisting of L-arginine, L-citrulline and L-ornithine, and c) L-ascorbic acid in which the mass ratio of Component b):Component c) is 1:0.2 to 20 is provided.
Abstract: A method of producing a population of differentiated cells comprising: a) inducing differentiation in a first population of cells by applying an inducer to said cells, b) harvesting microvesicles produced from first population of cells, and c) inducing differentiation in a second population of cells by applying said microvesicles or a derivative thereof to said second population of cells wherein, said first population of cells is autologous to said second population of cells and wherein the inducer applied to said first population of cells is not present in said second population of cells or is only present in trace amounts. Also related methods of producing microvesicles, methods of medical and/or cosmetic treatment and related products and uses.
Abstract: A method of preparing an amniotic membrane extract including the steps of obtaining a healthy amniotic membrane from a pregnant mammal, such as a pig, cow, horse or human, homogenizing the membrane to obtain a homogenate solution, freezing the homogenate solution, and lyophilizing the frozen homogenate solution to dryness is disclosed. Preferably, the lyophilized homogenate is pulverized to a powder. The lyophilized homogenate is then reconstituted before use, e.g., in a liquid, such as a balanced salt solution or fresh amniotic fluid, or in another substance, such a gel, an ointment, a cream or a soap, depending on the intended use. Also disclosed is a pharmaceutical composition prepared according to the method of the invention, for prophylaxis and/or treatment of a disease or condition, especially of the eye or the skin.
Abstract: The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities.
Type:
Application
Filed:
May 2, 2008
Publication date:
January 13, 2011
Applicant:
The McLean Hospital Corporation
Inventors:
Anne M. Cataldo, Peter A. Paskevich, Bruce M. Cohen
Abstract: The present invention concerns biologically-active cell-free scaffolds composed of extracts of cellular and/or extracellular compartments for use in tissue regeneration. The present invention also contemplates the novel concept of redesigning the biological scaffold by seeding cells thereon followed by cell elimination. Cells are seeded on the scaffold for a period of time during which a dynamic interaction occurs between the scaffold and the seeded cells, resulting in reshaping of the scaffold architecture and integration of newly synthesized matrix elements. Redesigning may improve the physical and biological characteristics of the scaffold, and also improve the matching of the scaffold to treat a specific target tissue or a specific patient, by seeding tissue-specific cells or by seeding cells which are autologous to a patient, respectively.
Abstract: We describe a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell. The biological property may comprise a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM) such as cardioprotection or reduction of infarct size. The particle may comprise a vesicle or an exosome.
Type:
Application
Filed:
February 21, 2009
Publication date:
January 6, 2011
Applicant:
Agency For Science, Technology And Research (A*STAR)
Abstract: A method of inducing the sustained release of antibodies in milk comprising the step of: a) implanting at least one antigen releasing device adjacent to, within close proximity of or within at least one supramammary lymph node, wherein in use the antigen releasing device releases an antigen into the tissue area around the supramammary lymph node which stimulates antibody secretion into a mammary gland.
Type:
Grant
Filed:
April 5, 2007
Date of Patent:
January 4, 2011
Inventors:
Kwang G. Tay, William J. Penhale, Peter M. Geerlings
Abstract: A cosmetic composition contains: a carotenoid (A), a collagen (B) having an average molecular weight of 40,000 or more, and a collagen peptide (C) having a weight average molecular weight of from 200 to 5,000.
Abstract: The invention encompasses methods of delivering nucleic acids, including dsRNA, to mammalian target cells in vivo via intercellular transfer, wherein the dsRNA is delivered to or expressed in a first cell different from the target cell, wherein the first cell facilitates delivery of the dsRNA to the target cell.
Abstract: We disclose a method of preparing a conditioned cell culture medium, the method comprising the steps of: (a) culturing a mesenchymal stem cell (MSC), a descendent thereof or a cell line derived therefrom in a cell culture medium; and (b) optionally isolating the cell culture medium; in which the mesenchymal stem cell (MSC) is obtained by propagating a cell obtained by dispersing a embryonic stem (ES) cell colony, or a descendent thereof, in the absence of co-culture in a serum free medium comprising FGF2.
Type:
Application
Filed:
August 15, 2007
Publication date:
December 23, 2010
Applicant:
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Abstract: The invention encompasses methods of decreasing the lumenal diameter of a blood vessel by contacting the vessel with a myosin light chain phosphatase inhibitor.
Abstract: The novel combinations of flubendiamide and beneficial species comprising flubendiamide and at least one beneficial species from the orders or suborders of the Araneae, Acari, Dermaptera, Hymenoptera, Coleoptera, Neuroptera, Thysanoptera, Heteroptera, Diptera, Hemiptera, Dermaptera and/or Parasitiformes or at least one bacteria strain or at least one virus strain for the effective control of unwanted pests.
Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
Type:
Grant
Filed:
November 3, 2004
Date of Patent:
December 7, 2010
Assignee:
Diagnostic Hybrids, Inc.
Inventors:
David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
Abstract: The present invention relates to dehydrated Type II collagen containing cartilage which has retained the collagen in its original crosslinked structure and which contains at least 40% by weight of the Type II collagen of an ionizable edible salt and which has a water content of less than 10%.
Abstract: The present invention provides for the identification of autoreactive T cell populations from individuals having autoimmune diseases, such as multiple sclerosis and EAE. Peptoids recognized by autoreactive T cells can be used to identify various types of autoimmune disease, and can also be used to target therapies against such populations.
Type:
Application
Filed:
May 28, 2010
Publication date:
December 2, 2010
Applicant:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Anne R. Gocke, D. Gomika Udugamasooriya, Thomas Kodadek
Abstract: The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response or an aberrant/enhanced Th1 response. More specifically, the present invention is directed to the treatment of Crohn's disease and ulcerative colitis, both known as IBD. While the present invention discloses specific information about the treatment of IBD, the disclosure is in no way limiting. Additionally, rheumatoid arthritis, type 1 diabetes mellitus, lupus erythematosis, sarcoidosis, multiple sclerosis, autoimmune thyroiditis, allergic rhinitis, colon polyps/colon cancer and asthma can be treated by the methods and compositions disclosed therein.
Type:
Application
Filed:
September 19, 2008
Publication date:
December 2, 2010
Applicant:
University of Iowa, The Research Foundation
Abstract: Therapeutic compositions and methods for using same for treating skin conditions and diseases are disclosed. Treatable skin conditions and diseases include without limitation acne vulgaris, rosacea, seborrheic dermatitis, eczema (atopic dermatitis), psoriasis, photo-aging and actinic keratosisacne vulgaris, psoriasis, photo-aging and eczema. Therapeutic compositions disclosed are derived from Porifera species, specifically sponges, and more specifically fresh water sponges. One disclosed embodiment is derived from Spongilla species and is formulated with pharmaceutically acceptable excipients.
Abstract: A biomaterial prepared from a process comprising dehydrating the fish scales until the fish scales containing less than about 50% of water, and grinding the dehydrated fish scales into ground particles each having an average size of less than about 10,000 ?m in diameter, wherein the ground particles contain a mixture of sponge like matrix and powder is provided. The invention also provides a biomaterial prepared from fish scales by a process comprising subjecting the fish scales to a heat treatment at a temperature of less than about 200° C.
Type:
Grant
Filed:
July 31, 2007
Date of Patent:
November 23, 2010
Inventors:
Chien-Cheng Lin, Horng-Ji Lai, Shang-Ming Lin
Abstract: Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.
Type:
Application
Filed:
May 6, 2010
Publication date:
November 11, 2010
Inventors:
Etzer Darout, Michael P. DeNinno, Kentaro Futatsugi, Cristiano Guimaraes, Bruce A. Lefker, Vincent Mascitti, Kim F. McClure, Michael J. Munchhof, Ralph P. Robinson
Abstract: Provided an acidic liquid preparation containing a herb and/or animal-origin extract at high concentration to suppress time-dependent occurrence of precipitation and/or opacity. A liquid preparation containing a herb-origin extract having pH of 3.0 to 5.5 and containing the herb-origin extract at a concentration of 5 to 50 w/v % (dry weight) to the total amount of the liquid preparation, containing a caramel at a concentration of 0.5 to 20 w/v % to the total amount of the liquid preparation, wherein the caramel has isoelectric point of 2.5 to 4.0 and 1.0 w/v % aqueous solution of the caramel has pH of 4.5 to 6.0. A liquid preparation containing an animal-origin extract having pH of 3.0 to 5.5 and containing the animal-origin extract at concentration of 5 to 50 w/v % (dry weight) to the total amount of the liquid preparation, containing a caramel at concentration of 0.5 to 20 w/v % to the total amount of the liquid preparation, wherein the caramel has isoelectric point of 0.5 to 4.0 and 1.
Abstract: A method of making encapsulated chromonic nanoparticles includes exposing crosslinked chromonic nanoparticles to an acid selected from the group consisting of carbonic acid, phosphoric acid, lactic acid, citric acid, boric acid, sulfuric acid, and mixtures thereof in the presence of water to encapsulate the crosslinked nanoparticles in a shell comprising a complex comprising the chromonic material, the multivalent cations, and the acid anions.
Type:
Grant
Filed:
December 28, 2005
Date of Patent:
November 2, 2010
Assignee:
3M Innovative Properties Company
Inventors:
Hassan Sahouani, Sanat Mohanty, Cristin E. Moran
Abstract: A composite tissue formed in situ is provided. The composite tissue includes a synovial joint tissue; and a barrier material adhered thereto for sealing the synovial joint tissue against synovial fluid. Also provided is a method for regenerating synovial joint tissue in situ by excluding synovial fluid therefrom. The method includes providing a synovial joint tissue having a defect; and placing a barrier material in intimate contact with the defect for sealing the defect against synovial fluid. The barrier material includes a curable protein copolymer. The method further includes curing the protein copolymer in situ. The barrier material can include a crosslinked network, or a self gelled network of repeating elastin-like and fibroin-like polymer chains.
Abstract: A composition for use in cardiovascular therapy includes transfer factor. The transfer factor may be nonmammalian transfer factor, such as that derived from eggs, or mammalian transfer factor, such as that derived from colostrum. The composition may also include one or more of the following: an LDL receptor-binding element; a blood flow-enhancing element; a cholesterol reducing element; a fat oxidation prevention element, and an antioxidant. Treatment methods include enlisting the immune system of a subject receiving therapy to attack pathogens that cause inflammation of blood vessels or to otherwise reduce inflammation of blood vessels.